SCHEMBL4334983

SCHEMBL4334983

O=C(Nc1ccc2[nH]nc(-c3cc4ccccc4s3)c2c1F)C1CCCO1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 1/20 0.49
NPC1 O15118 8/20 0.46
RAB9A P51151 7/20 0.46
SMN1; SMN2 Q16637 7/20 0.46
TP53 P04637 2/20 0.46
MAPK1 P28482 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
TSHR P16473 1/20 0.42
PIP5K1C O60331 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343158 0.87 MAPK10 (0.54) MAPK10NPC1RAB9ASIRT2SIRT1
SCHEMBL4338569 0.83 ADORA3 (0.46) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL4345714 0.81 MAPK10 (0.46) MAPK10SMN1; SMN2SIRT2SIRT1POLB
SCHEMBL4337637 0.77 MAPK1 (0.45) MAPK10NPC1RAB9ASMN1; SMN2TP53
SCHEMBL4329385 0.76 STK33 (0.44) MAPK10NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL2862233 0.76 MEN1 (0.45) MAPK10NPC1RAB9ASMN1; SMN2TP53
SCHEMBL2857326 0.76 PIP5K1C (0.48) MAPK10NPC1RAB9ASMN1; SMN2TP53
SCHEMBL4335786 0.74 MAPK10 (0.52) MAPK10SIRT2SIRT1ALDH1A1KDM4E
SCHEMBL2861026 0.73 TNIK (0.49) MAPK10SIRT2SIRT1
SCHEMBL2859049 0.73 MAPK10 (0.43) MAPK10SIRT2SIRT1PIP5K1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK10 29/4885NPC1 1164/4885RAB9A 2355/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK10 29/4885NPC1 1164/4885RAB9A 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.